ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.26% | 10.45% | -47.44% | -15.52% | 0.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.26% | 10.45% | -47.44% | -15.52% | 0.58% |
| Cost of Revenue | -0.81% | 28.19% | -83.98% | 107.61% | -6.58% |
| Gross Profit | -59.12% | -5.26% | 87.97% | -105.57% | 6.62% |
| SG&A Expenses | -28.73% | -10.11% | 0.97% | -6.92% | -25.66% |
| Depreciation & Amortization | -76.36% | -74.28% | -20.01% | -0.70% | -8.04% |
| Other Operating Expenses | -93.65% | -95.43% | -60.48% | -83.33% | -65.92% |
| Total Operating Expenses | -45.04% | -29.74% | -11.57% | -18.04% | -15.28% |
| Operating Income | 45.37% | 31.07% | 10.52% | 18.13% | 15.68% |
| Income Before Tax | 32.90% | 20.18% | 58.93% | 8.80% | 9.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.90% | 20.18% | 55.08% | 8.40% | 9.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.90% | 20.18% | 55.08% | 8.40% | 9.07% |
| EBIT | 45.37% | 31.07% | 10.52% | 18.13% | 15.68% |
| EBITDA | 39.00% | 20.14% | 8.50% | 22.40% | 17.10% |
| EPS Basic | 37.12% | 25.88% | 57.85% | 15.08% | 14.72% |
| Normalized Basic EPS | 36.74% | 25.86% | -3.48% | 15.60% | 15.11% |
| EPS Diluted | 35.02% | 22.37% | 57.87% | 8.79% | 15.23% |
| Normalized Diluted EPS | 36.74% | 25.86% | -3.48% | 15.60% | 15.11% |
| Average Basic Shares Outstanding | 6.49% | 7.76% | 6.63% | 7.97% | 6.73% |
| Average Diluted Shares Outstanding | 6.49% | 7.76% | 6.63% | 7.97% | 6.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |